Clinical trials: Metastatic Disease
Non-Hodgkin's Lymphoma, Solid Cancers
A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable
This is an open-label, Phase I, dose-escalation study using a 3 + 3 design to assess the safety, tolerability, and pharmacokinetics of orally administered GDC-0941 administered QD.
- Trial name
- NCT00876122
- Testing
- GDC-0941
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Genentech, Inc.
Metastatic Spine Tumor
Metastatic Tumor Research and Outcomes Network
The registry aims to collect patient information such as patient demographics, co-morbidities, clinical, diagnostic, and therapeutic data, as well as information on adverse events and HRQOL outcomes specific for patients with…
- Trial name
- MTRON (NCT02830451)
- Where
- 24 sites in United States, Australia and 8 more
- Volunteers
- 2,417 people
- Sponsor
- AO Innovation Translation Center
Leukemia, Lymphoma
Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
RATIONALE: Giving chemotherapy before a donor umbilical cord blood transplant helps stop both the growth of cancer cells and the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00301951
- Testing
- anti-thymocyte globulin, sargramostim, busulfan
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, San Francisco
Solid Cancer
A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed
The purpose of this study is to enable participants, currently receiving regorafenib in a Bayer-sponsored clinical trial, to continue treatment after their respective study has been closed.
- Trial name
- NCT03890731
- Testing
- BAY73-4506 (Regorafenib, Stivarga)
- Where
- 6 sites in United States, Germany and 3 more
- Volunteers
- 6 people
- Sponsor
- Bayer
Colorectal Cancer Metastatic, Cancer
The Effect of ePRO on Quality of Life and Prognosis of Patients With Unresectable Metastatic Colorectal Cancer
Bevacizumab combined with fluorouracil-based chemotherapy is the first-line standard treatment for patients with metastatic colorectal cancer (mCRC).
- Trial name
- NCT04684095
- Testing
- electronic patient report outcome
- Where
- China
- Volunteers
- 338 people
- Sponsor
- Harbin Medical University
Lung Cancer and Breast Cancer Patients With Brain Metastases
A Phase II Multi-center Pilot Study of Concurrent Temozolomide and Whole Brain Irradiation in Lung Cancer and Breast Cancer Patients With Brain Metastases
Brain metastasis (BM) is among the most feared complications in cancer because even small tumors may cause incapacitating neurologic symptoms.
- Trial name
- NCT02133677
- Testing
- temozolomide 100mg
- Where
- Taiwan
- Volunteers
- 24 people
- Sponsor
- Far Eastern Memorial Hospital
Antiphospholipid Syndrome, Thrombosis
Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome
This study is designed to compare the safety and effectiveness of two blood thinners, apixaban and warfarin, for the prevention of blood clots in patients who have a higher risk of blood clots than the general population, a…
- Trial name
- ASTRO-APS (NCT02295475)
- Testing
- Apixaban, Warfarin
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Scott C. Woller, MD
Biliary Tract Neoplasms
TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract Cancer
TST001 is a recombinant humanized anti-Claudin 18.2 (CLDN18.2) IgG1 monoclonal antibody. This is an open-label, single-arm phase II study to evaluate the efficacy and safety of TST001 for patients with CLDN18.2 positive…
- Trial name
- NCT05190575
- Testing
- TST001
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Shanghai Zhongshan Hospital
Triple Negative Breast Cancer, Metastatic Breast Cancer
Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer
ISIdE is an European, multicentric study that aims to assess the efficacy of Sacituzumab Govitecan (SG) in locally advanced or metastatic triple-negative breast cancer where the disease has progressed despite chemotherapy or…
- Trial name
- ISIdE (NCT05552001)
- Testing
- Sacituzumab govitecan
- Where
- France
- Volunteers
- 96 people
- Sponsor
- UNICANCER
Metastatic Cancer
Measurement and Characterization of Circulating Endothelial Cells or Circulating Tumor Cells or Circulating DNA in Adult Patients With Metastatic Cancer
Monitoring of circulating endothelial cells (CEC and mature cells called progenitors called CEP) or circulating tumor cells (CTC) in adult patients with metastatic cancer, possibly treated with targeted therapy.
- Trial name
- Liquid Biopsy (NCT02666612)
- Testing
- Blood samples
- Where
- France
- Volunteers
- 2,240 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Solid Tumor, Cancer Metastatic
Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors
To evaluate CAN1012(Selective TLR7 agonist) when administered by IT injection to subjects with advanced solid tumors who are not candidates for standard therapy.
- Trial name
- NCT04987112
- Testing
- CAN1012
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- CanWell Pharma Inc.
Liver Cancer
Pharmacokinetics of Doxorubicin in cTACE of Liver Cancer
Patients with primary and secondary liver cancer may participate in this study. The purpose is to perform an analysis of the effects of doxorubicin and its metabolite doxorubicinol on the body (doxorubicin pharmacokinetics )…
- Trial name
- NCT02753881
- Testing
- whole liver lobe cTACE doxorubicin, superselective cTACE doxorubicin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Yale University
Metastatic Urothelial Cell Cancer
A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients
This is a single arm, open-label phase Ib study of combining eribulin mesylate with avelumab. The initial 9-12 patients (MTD cohort) will be enrolled to determine safety of avelumab in combination with eribulin mesylate.
- Trial name
- NCT03502681
- Testing
- Eribulin Mesylate, Avelumab
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Monika Joshi, MD
CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain
Genetic Testing in Guiding Treatment for Patients With Brain Metastases
This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain.
- Conditions
- CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation
- Trial name
- NCT03994796
- Testing
- Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib
- Where
- 435 sites in United States
- Volunteers
- 50 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Stage IV or Recurrent Carcinoma or Sarcoma
Definitive Therapy for Oligometastatic Solid Malignancies
Patients with metastatic cancer are usually treated with systemic therapy (treating the entire body) with the assumption that any localized treatment of clinically apparent metastases would not impact survival.
- Trial name
- NCT01898962
- Testing
- Complete Surgical Removal, Stereotactic Radiosurgery, Ablative external beam radiation dose
- Where
- 4 sites in United States
- Volunteers
- 110 people
- Sponsor
- Rocky Mountain Cancer Centers
Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)
This is a multicenter, randomized, open-label, Phase 2/3 study that will evaluate the efficacy and safety of bempegaldesleukin (BEMPEG; NKTR-214) combined with pembrolizumab compared with pembrolizumab monotherapy in patients…
- Trial name
- NCT04969861
- Testing
- Bempegaldesleukin, Pembrolizumab
- Where
- 4 sites in United States, Austria and 2 more
- Volunteers
- 1 people
- Sponsor
- Nektar Therapeutics
Prostate Cancer, Prostatic Neoplasms
Predictive Factors for Response to Lutetium-177 PSMA Radioligand Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
The goal of this observational study is to learn which factors can predict how well lutetium-177 PSMA therapy works in people with metastatic castration-resistant prostate cancer (mCRPC).
- Conditions
- Prostate Cancer, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Neoplasm Metastases
- Trial name
- NCT07863986
- Testing
- [177Lu]Lu-PSMA-617 (Pluvicto, Novartis), 68Ga-PSMA-11 PET/CT, Post-therapy 177Lu-PSMA SPECT/CT dosimetry
- Where
- Lithuania
- Volunteers
- 70 people
- Sponsor
- Lithuanian University of Health Sciences
Thymic Tumors
A Study of KC1036 in Patients with Advanced Thymic Tumors
This is a single arm，open-label, multicentric, phase II study to evaluate the efficacy and safety of KC1036 in patients with advanced recurrent or metastatic thymoma or thymic carcinoma.
- Trial name
- NCT05683886
- Testing
- KC1036
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
This pilot trial studies the side effects of giving pembrolizumab together with stereotactic radiosurgery to treat patients with melanoma or non-small cell lung cancer that has spread to the brain.
- Conditions
- Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Mucosal Melanoma, Ocular Melanoma
- Trial name
- NCT02858869
- Testing
- Pembrolizumab, Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Emory University
Non-Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV
Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC
The third generation epidermal growth gactor receptor-tyrosine Kinase Inhibitor（EGFR-TKI） osimertinib has obvious curative effect for EGFR sensitive mutation and T790M mutation(PMID 27959700), but acquired drug resistance will…
- Conditions
- Non-Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV, EGFR T790M
- Trial name
- NCT03543683
- Testing
- Osimertinib, Aspirin
- Where
- China
- Volunteers
- 115 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University